Trials / Completed
CompletedNCT00406562
Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age.
Open, Booster Vaccination Study to Assess Safety and Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Administered to Healthy Chinese Children 6-8 Years of Age.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 30 (planned)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 6 Years – 8 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate the safety and reactogenicity of booster dose of GSK Biologicals' dTpa vaccine (Boostrix) in Chinese children at 6-8 years of age.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Boostrix |
Timeline
- Start date
- 2007-01-01
- Completion
- 2007-02-01
- First posted
- 2006-12-04
- Last updated
- 2016-10-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00406562. Inclusion in this directory is not an endorsement.